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Doxycycline delays aneurysm rupture in a mouse
model of Marfan syndrome
Wanfen Xiong, PhD,a Rebecca A. Knispel, BS,a Harry C. Dietz, MD,b Francesco Ramirez, PhD,c and
B. Timothy Baxter, MD,a Omaha, Neb; Baltimore, Md; and New Brunswick, NJ
Objectives: Thoracic aneurysms are the main cardiovascular complication of Marfan syndrome (MFS) resulting in
premature death. MFS has been associated with mutations of the gene encoding fibrillin-1 (FBN1), a major constituent
of the elastic fibers. Matrix metalloproteinases (MMPs) are important in the pathogenesis of abdominal aortic aneurysms
but their precise role in MFS is not clear. Doxycycline is a nonspecific MMP inhibitor. The objective of the study was to
determine whether docycycline can attenuate matrix degradation and prolong the survival of mice with MFS.
Methods: The study employed a well-characterized animal model of MFS, namely fibrillin-1 under-expressing mice
(mgR/mgR mice) that die spontaneously from rupture of the thoracic aorta between 2 to 4 months of age. Mutant and
wild type mice were given doxycycline in their drinking water at a concentration designed to provide 100 mg/kg/day
beginning at postnatal day (PD) 1, whereas control mice were given water. Treated mice were divided into two groups.
One group of animals was followed until death or for 7 months to determine lifespan. In the second group of mice, the
ascending thoracic aortas were collected for histological analysis (H&E staining, trichrome staining) and zymography for
examining MMP-2 and MMP-9 levels at 6 weeks.
Results: MMP-2 and MMP-9 levels were higher in the thoracic aorta of mgR/mgR mice compared with wild type
littermates. Doxycycline-treated mgR/mgR mice lived 132  14.6 days (n  16) or significantly longer than untreated
mutant mice (79 6.7 days, n 30) (P< 0.01). Connective tissue staining showed that doxycycline treatment decreased
elastic fiber degradation in mgR/mgR mice. Furthermore, mgR/mgR mice treated with doxycycline had lower MMP-2
and MMP-9 levels compared with untreated mgR/mgR mice.
Conclusions: This study demonstrates that doxycycline significantly delays aneurysm rupture in MFS-like mice by
inhibiting expression of tissue MMP-2 and MMP-9 and thus, degradation of the elastic matrix. The results suggest that
MMPs contribute to the progression of thoracic aneurysm in MFS and that doxycycline has the potential to significantly
alter the course of the disease. ( J Vasc Surg 2008;47:166-72.)
Clinical Relevance: Aortic aneurysms are the main cardiovascular complication of Marfan syndrome (MFS) resulting in
premature death. -blockers offer some benefit but do not address the underlying cause of the progressive aortic degradation.
Medical treatment that actually targets recently identified pathogenic factors leading to progressive matrix destruction could
significantly impact the clinical course of the disease. A recent study using amousemodel ofMFS has demonstrated that TGF-
 antibodies or the angiotensin II type I receptor (AT1) antagonist losartan can both effectively rescue aneurysm progression.
Wehave found that doxycycline, a nonspecific inhibitor ofmatrixmetalloproteinases (MMPs), candecrease elastin degradation
and prolong the lifespan of genetically engineered mice that mimic the human disease process. Based on these results, further
testing may be warranted to determine if doxycycline could favorable impact the natural history of Marfan syndrome.Marfan syndrome (MFS) is an inherited disorder of the
connective tissue with prominent abnormalities in the oc-
ular, skeletal, and cardiovascular systems.1 The most com-
mon cardiovascular manifestation in patients with MFS is
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166progressive aortic root dilatation that can precipitate life-
threatening complications, such as aortic regurgitation,
dissection, or rupture. MFS is caused by mutations in the
gene encoding fibrillin-1 (FBN1), the major constituent of
extracellular microfibrils.2,3 Fibrillin-rich microfibrils are
found in a wide variety of connective tissues, either associ-
ated with elastin in the elastic fibers or as elastin-free
assemblies.4 Experimental evidence and biosynthetic con-
siderations originally predicted that FBN1 mutations in
MFS would reduce tissue integrity by interfering with the
normal assembly of microfibrils. The combination of a
structurally impaired tissue and chronic cyclic stress was
believed to be the main cause of the mechanical failure of
the aorta.4 This concept was recently revised by the studies
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driven secondary cellular events in the progression of aortic
aneurysm.5-7 These studies have also documented the abil-
ity of TGF- antagonism to effectively rescue aortic aneu-
rysm in MFS-like mice.8 Additional work in mutant mice
has indicated that proteolysis of fibrillin-rich microfibrils
contributes to aneurysm progression as well by stimulating
macrophage chemotaxis and the expression of matrix met-
alloproteinases (MMPs).9,10
MMPs represent a family of zinc endopeptidases that
are responsible for the degradation of the extracellular
matrix (ECM) in abdominal aortic aneurysms (AAAs).11-13
It has been demonstrated in previous studies that MMP-2
frommesenchymal cells andMMP-9 frommacrophages are
required for aneurysm formation.14 Studies of aneurysm
tissues from patients withMFS suggest that upregulation of
MMP-2 and MMP-9 may also play a primary role in
MFS.15,16 Doxycycline is a nonspecificMMP inhibitor that
has been used to treat a number of conditions associated
with excess MMP expression, including periodontal disease
and rheumatoid arthritis.17-20 Experimental AAAs are in-
hibited by doxycycline and a single small randomized trial
demonstrated suppression of aortic aneurysm expansion by
doxycycline.21-23 Previous work from our laboratory has
shown that doxycycline inhibits MMP-2 secretion from
explanted human AAA tissue.24 These findings provide
evidence that doxycycline can effectively treat diseases in
which MMPs play a pathogenic role. Based on these data,
we hypothesized that doxycycline could delay spontaneous
rupture of the thoracic aorta in mice with MFS by inhibit-
ing MMP-2 and MMP-9.
The present study was designed to test the above
hypothesis by examining the effects of doxycycline treat-
ment in mice with MFS that typically develop thoracic
aneurysms and die spontaneously from rupture of the prox-
imal aorta at between 2 to 4 months of age.5 The results
showed that doxycycline treatment significantly prolonged
the survival of the mutant mice while reducing MMP
expression and improving histopathological signs of aortic
matrix degradation compared with placebo-treated control
animals. These findings strongly suggest that doxycycline
has the potential to significantly alter the course of the
disease in MFS patients.
METHODS
Mice. Heterozygous mutant mice (mgR/) in a
mixed C57Bl/6J;129 SvEv background were mated to
generate homozygous mutant mice (mgR/mgR) and
wild type littermates.5 Genotyping of mice was per-
formed at post-natal day 14 (P14) by polymerase chain
reaction (PCR) using deoxyribonucleic acid (DNA)
from tail biopsies and the following primers to amplify
the wild type and mgR allele, respectively: (5’-CTC-
CGTGGGACCTACAAATG-3’ and 5’-CCAGGTGT-
GTTTCGACATTG-3’) and (5’-CTCCGTGGGAC-
CTACAAATG-3’ and 5’-TGAATGAACTGCAGGAC-
GAG-3’). All experiments were carried out in accordance
with the guidelines of the University of Nebraska Med-ical Center Animal Care Committee for the use and care
of laboratory animals. All mice were maintained in the
pathogen free animal facility.
Doxycycline treatment and Kaplan-Meier’s survival
curve. Beginning on postnatal day (PD)1, mouse mothers
were given plain water or doxycycline containing drinking
water. The concentration of doxycycline in the water was
calculated to provide 100 mg/kg/day based on average
daily water intake. We have shown in a previous study that
this concentration of doxycycline achieved a mean plasma
concentration of 4.14 0.557.22 Serum doxycycline levels
at these doses were similar to the plasma doxycycline levels
of AAA patients taking 200 mg of doxycycline per day.22
One group of wild type littermates (n 18) and one group
of homozygous MFS mice (n  17) with or without
doxycycline treatment were sacrificed at 6 weeks of age.
The ascending thoracic aortas were perfusion-fixed with
10% neutral buffered formalin and collected for histological
studies.25 Some of the samples were snap frozen in liquid
nitrogen for protein extraction and zymographic analysis.25
To configure the Kaplan-Meier survival curve, mice were
evaluated daily and survival recorded. Mice were followed
up to 7 months, at which time, all surviving mice were
sacrificed.
Masson’s trichrome connective tissue staining.
Mouse ascending thoracic aortas were harvested, perfu-
sion-fixed with 10% neutral buffered formalin, embedded
in paraffin, and cut into 4 m sections. The slides were
stained with hematoxylin, Crocein Scarlet, Acid Fuchsin,
and Aniline Blue (Sigma, St. Louis, Mo). Each staining
cycle alternated between fixing and washing procedures.
The slides were examined and photographed using light
microscopy (Kodak) (40).
Gelatin zymography. Mouse aortic protein was ex-
tracted as described previously.25 The protein content of
the aortic samples was determined by protein assay (Bio-
Rad Laboratories, Hercules, Calif) and equalized by pro-
tein content for loading. Gelatin zymography was con-
ducted using sodium dodecyl sulfate (SDS)-polyacrylamide
gels containing 0.8 % gelatin (Sigma, St. Louis, Mo). After
electrophoresis, the gels were washed five times in a Triton
X-100 solution (50 mM Tris-HCl (pH 7.5)/5 mM
CaCl2/1 M ZnCl2/ 0.02 %NaN3/ 2.5 %Triton X-100)
to remove the SDS and renature the gelatinases. Gels were
then developed in the same buffer excluding Triton X-100
(development buffer) overnight at 37oC. Enzymatic activ-
ity was visualized as negative staining with 0.5 % Coomassie
Brilliant Blue R-250 (Sigma, St. Louis, Mo). The molecu-
lar sizes of gelatinolytic activity were determined by com-
parison with Molecular Weight Markers (Bio-Rad, Her-
cules, Calif). The gelatinolytic activities were quantified by
Bio-Rad densitometer and Quantity One Quantification
Software (Bio-Rad, Hercules, Calif).
Reverse zymography. Aortic proteins were separated
by electrophoresis on 12.5% SDS-PAGE copolymerized
with 1.6% gelatin and 0.16 g/ml MMP-2. After electro-
phoresis, the SDS was removed from the gel by washing in
2.5% Triton X-100 for 2 hours. The gels were incubated at
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0.5% Coomassie brilliant blue G-250 (Sigma) for 2 hours,
and destained in gel-destaining buffer (40% methanol and
10% glacial acetic acid) until the background was clear. The
molecular sizes of gelatinolytic activity were determined by
comparison with Molecular Weight Markers (Bio-Rad).
The band intensities were quantified by Bio-Rad densitom-
eter and Quantity One Quantification Software (Bio-Rad).
Statistical analyses. Data are presented as mean SE.
Life table analysis was used for the Kaplan-Meier survival
curve. Statistical significance (P  .05) for all other vari-
ables was determined by analysis of variance (ANOVA).
RESULTS
Doxycycline prolongs the lifespan of MFS-like mice. In
preliminary analysis, we performed necropsy on all Marfan
mice that died.We found that 10/10 deaths were related to
blood loss from ruptured ascending aneurysms. The aim of
the study was to investigate whether doxycycline could
prevent MFS-associated aortic rupture and extend the life-
span of mgR/mgR mice.5 Accordingly, doxycycline or
placebo (water) was administered tomgR/ dams in order
to transmit the drug via the breast milk to homozygous
mgR pups and their wild type littermates. This treatment
lasted between P1 and P28 and was followed by direct
administration of either water or water containing doxycy-
cline to the two experimental samples after weaning. Mor-
tality was recorded in both groups, while mice that survived
past 7 months were sacrificed. Homozygous mice treated
with doxycycline at 100mg/kg lived 132 14.6 days (n
16), significantly longer than the untreated mice that sur-
vived 79  6.7 days (n  30) (P  .01) (Fig 1). These
results demonstrated that doxycycline can significantly pro-
long the lifespan of MF mice.
MMP-2 and MMP-9 expression in aortas. We then
examined MMP-2 and MMP-9 levels in the aorta of wild
type and mgR/mgR mice that were sacrificed at 6 weeks of
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Fig 1. The effect of doxycycline on the survival of mgR/mgR
mice. Mice were treated with doxycycline (doxy) (100 mg/kg) or
regular water (no doxy) daily, started at the age of 1 day. Life table
analysis shows improved survival in mice treated with doxycycline
(P  .0009).age. Zymographic analysis showed that MMP-2 andMMP-9 levels were increased in mgR homozygous mouse
aorta compared with wild type control mice (Fig 2). These
findings suggested that MMP-2 and MMP-9 could play a
role in the pathogenesis of aneurysm disease in this mouse
model of MFS. In order to determine if the doxycycline
treatment impacted MMP-2 and MMP-9 production, we
examined MMP-2 and MMP-9 production in doxycycline
treated mgR homozygous mice. The MMP-2 and MMP-9
levels were significantly reduced in doxycycline treatment
(Fig 2). Levels of tissue inhibitors of metalloproteinases 1
and 2 (TIMP-1 and TIMP-2) are not significantly different
among WT, or mgR/mgR with or without doxycycline
treatment (Fig 3). The data suggested that doxycyclinemay
prevent aneurysm rupture by inhibiting MMP-2 and
MMP-9 production.
Histological changes. MMPs contribute directly to
the degradation and remodeling of ECM. Therefore, it is
possible that doxycycline treatment can prevent elastic fiber
fragmentation. We further studied histological changes in
aorta. The number of breaks in the elastin was quantified by
an observer unaware of the genetic background or treat-
ment of the mice. Connective tissue staining of aortic
sections frommgR/mgRmice showed disruption and frag-
mentation of medial elastic fibers (Fig 4, c), while wild type
Fig 2. Gelatin zymographic analysis of MMP-2 and MMP-9 in
the mouse thoracic aortas. Mouse thoracic aortas from wild type
control, mgR/mgR, and doxycycline-treated mgR/mgR mice
harvested at 6 weeks of age (n  5 mice/group). Aortic proteins
were extracted and separated by electrophoresis on a 10% SDS-
PAGE containing 0.8% gelatin. Band intensities (gelatinolytic ac-
tivities) were measured by densitometer. Relative expression of
MMP-9 and MMP-2 in wild type control, mgR/mgR, and doxy-
cycline-treated mgR/mgR mouse aortas was analyzed. *, # P 
0.05 (*relative to wild type controls, # relative to untreated mgR/
mgR mice). A representative gel is shown.controls showed intact medial elastic lamella (Fig 4, b).
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doxycycline-treated mgR/mgR mice was indistinguishable
from that in the wild type control mice (Fig 4, d). Quanti-
fication of the number of breaks in the elastic lamellae
shows significantly fewer breaks in the elastin among the
docycycline-treated mgR/mgR mice compared with un-
treated mgR/mgR mice (Fig 4, a). We therefore conclude
that doxycycline can significantly alter the course of the
disease.
DISCUSSION
Aneurysms of the ascending aorta are the main cardio-
vascular complication of MFS. In this study, we have used
mgR/mgR mice, a well-characterized mouse model of
MFS,5,6 in order to examine the potential of doxycycline, a
nonspecific MMP inhibitor, to prevent aneurysm rupture.
To understand themechanism of action of doxycycline in this
Fig 3. Reverse zymographic analysis of TIMP levels in the mouse
thoracic aortas. Mouse thoracic aortas from wild type control,
mgR/mgR, and doxycycline-treated mgR/mgRmice harvested at
6 weeks of age (n 5mice/group). Aortic proteins were separated
by electrophoresis on a 12.5% SDS-PAGE containing 1.6% gelatin,
0.16 g/ml MMP-2. A representative reverse zymogram shows
the bands representing gelatin preserved by TIMP-1 and TIMP-2
(indicated by arrows). Band intensities were measured by densi-
tometer. Relative expression of TIMP-1 and TIMP-2 in wild type
control, mgR/mgR, and doxycycline-treated mgR/mgR mouse
aortas was analyzed.model, we assessedMMP-2 andMMP-9 levels and changes inthe aortic histopathology. Doxycycline treatment was able to
delay aneurysm rupture and prolong the mgR homozygous
mouse lifespan. MMP-2 andMMP-9 levels were found to be
significantly higher in the thoracic aorta of mgR/mgR mice
than in wild type littermates. Connective tissue staining
showed that doxycycline treatment prevented or delayed elas-
tic fiber fragmentation and lowered MMP-2 and MMP-9
expression in mgR homozygous mice.
Fibrillin-1 is the principal structural component of ex-
tracellular microfibrils that confer mechanical properties to
connective tissues, alone or in association with elastin in the
elastic fibers.26 Fibrillin-1 mutations are responsible for the
pleiotropic manifestations of MFS, which include the life-
threatening complications of the cardiovascular system.1
Several mouse models of MFS have been created that have
provided new insights into aortic disease progression in
MFS.4 The mgR/mgRmouse model, in particular, was the
first to show that fibrillin-1 deficiency promotes a series of
secondary cellular events that exacerbate the progression of
aneurysmal disease leading to dissection.5,6 These patho-
genic events include localized aortic calcium deposition,
inflammatory cell infiltration, fibrosis, increased expression
ofMMPs, and elastic lamellae degradation. Consistent with
these findings, Marque et al27 have shown that reduced
expression of fibrillin-1 in mgR/mgR mice leads to severe
elastic network fragmentation but no change in cross-
linking suggesting that fragmentation of the medial elastic
network was not related to a defect in early elastogenesis.
Likewise, Guo et al10 have reported that addition of aortic
extracts from mgR/mgR mice to cell culture systems stim-
ulates the expression of MMPs and macrophage chemo-
taxis. Other mouse models have correlated the emergence
of pulmonary and cardiac valve manifestations with higher
than normal TGF- activity.7,28 Finally, a recent study
using the C1039G/ mouse model of MFS has demon-
strated that TGF- antibodies or the angiotensin II type I
receptor (AT1) antagonist losartan can both effectively
rescue aneurysm progression.8
Our study expands knowledge of the factors contribut-
ing to vascular disease in MFS by demonstrating that MMP
production is increased in mgR/mgR mice. These obser-
vations confirm the findings of Bunton et al6 who reported
elevated tissue MMP levels in another model of MFS.
Furthermore, the efficacy of doxycycline, an MMP inhibi-
tor, in reducing MMP levels and elastin degradation and
improving survival, demonstrates the role of MMPs in
progression of MFS. The study suggests that MMP inhibi-
tion is a strategy that deserves consideration in patients with
MFS. MMPs are a family of Ca2-activated, Zn2-depen-
dent endopeptidases that are able to degrade components
of ECM by their concerted actions. The elastin and colla-
gen degradation in abdominal aortic aneurysm tissue is
mediated by members of the MMP family, especially
MMP-9 and MMP-2.29-31 MMP-9 is one of the most
abundant elastolytic proteinases secreted by human AAA
tissues. It is primarily produced by aneurysm-infiltrating
macrophages at the sites of tissue damage and its expression
appears to correlate with increasing aneurysm diame-
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is primarily the product of resident mesenchymal cells.34
Both of these enzymes are required for experimental aneu-
rysm induction in the abdominal aorta of the mouse.14
Some studies suggest that upregulation of MMP-2 in vas-
cular smooth muscle cells plays a primary role in MFS
aneurysm development 15,16 Bunton et al6 and Neptune et
al7 have respectively shown greater expression of MMPs in
the aorta and lung tissue of mgR/mgR mice. Our current
study showed that MMP-2 and MMP-9 production was
significantly increased inmgR homozygous mice compared
with normal control mice. TIMP-1 levels showed more
variability than TIMP-2 levels; there were no differences in
TIMP levels among the groups. The effectiveness of the
MMP inhibitor doxycycline in decreasing MMP-2 and
MMP-9 production and prolonging survival demonstrate,
for the first time, that MMPs play an important etiologic
role in the progression of thoracic aneurysms in MFS.
Doxycycline has been used to treat several conditions
associated with elevated MMPs. A number of studies have
shown that doxycycline can inhibit experimental AAAs and
reduce MMP expression in aneurysm tissues 21,35,36 Work
from our laboratory has shown that doxycycline at standard
therapeutic serum concentrations inhibits MMP-2 produc-
tion from cultured human aortic smooth muscle cell
(SMC) and AAA tissue explants.24 Doxycycline inhibits
aneurysm growth in a murine aneurysm model.22 The
Fig 4. Elastic fiber degradation in the wild type (WT)
magnification in WT, mgR/mgR, and doxycycline-trea
(*relative to wild type controls, # relative to untreatedmg
of aortic tissue of WT (b), mgR/mgR (c), and doxyc
indicates breaks in elastic fibers.precise mechanism by which doxycycline inhibits MMPsremains to be fully elucidated. A recent study has shown
that doxycycline, at pharmacologically achievable nontoxic
doses, inhibits TGF-  -induced MMP-9 production and
activity through the Smad and MAPK signaling pathway in
corneal epithelial cells.37 A study by Yoshimura et al dem-
onstrated that JNK is a proximal signaling molecule in the
pathogenesis of AAAs and selective inhibition of JNK in
vivo not only prevented the development of AAAs but also
caused regression of established mouse AAAs.38 Prelimi-
nary data from one of our laboratories indicates that JNK
signaling is altered in the aortic smooth muscle cells of mice
with MFS (FR unpublished data).
In conclusion, this study provides the proof of principle
that doxycycline can inhibit MMP-2 and MMP-9 produc-
tion and aortic elastic fiber fragmentation, thus delaying
aneurysm rupture, in this mouse model of MFS. While
MMP inhibition appears to be the primary mechanism
through which doxycycline protects the aorta, further work
is needed to determine if doxycycline may also affect up-
stream mediators of matrix metabolism such as TGF- and
JNK. Since losartan blocks the Smad2 phosphorylation, ie,
TGF- signaling, doxycycline and losartan may work to-
gether to block matrix degradation in MFS. Because of the
safety profile of the tetracyclines and the potential lethality
of MFS, prospective clinical trials should be considered to
determine if doxycycline can delay progression of aortic
mgR/mgR mice. a, elastin breaks per field under 40x
gR/mgR mice (n  3 aortas/group). *, # P  0.05
gRmice). b, c, and d, representative trichrome stainings
-treated mgR/mgR (d) mice at 6 weeks age. Arrowsand
ted m
R/m
yclinedisease in patients with MFS.
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Dr J. Matsumura (Chicago, Ill). What further work must be
done, or is doxycycline ready for a human trial in Marfan syndrome?
Dr Baxter. The question is how do you know if your treat-
ment is helping in a disease that may progress very slowly over
decades? It’s easy to look at a mouse that only lives several months.
Before going to a patient trial, it would be helpful to have some
sort of plasmamarker that would bemore dynamic than the change
in aortic diameter.
Dr R. Thompson (St. Louis, Mo). I have a question about the
previous use of this model to test the effects of losartan as a
potential treatment for Marfan syndrome, which is now being
applied in clinical trial. Do you know how the efficacy of treatment
with doxycycline compares with losartan in this same mouse
model, and have you tried any experiments using both of those
pharmacologic therapies?
Dr Baxter. We have not used losartan yet. And our collabo-
rators on this project, Dr Dietz and Dr Ramirez, presented their
work in Science showing that they could reverse some of the
changes in another model that they developed of Marfan syn-
drome. They have not done the survival curves as we did in this
trial, so they really do not know if it is going to prolong the lifespan
of those mice or how this would compare with doxycycline.
Dr Thompson. As a follow-up, can I ask how doxycycline
affects the secondary manifestations of Marfan syndrome in these
mice, such as skeletal myopathy and pulmonary emphysema, which
losartan has also been shown to influence?
Dr Baxter. The answer to that is we do not know. We did not
study those things. But obviously that would be important.
Dr J. Black (Baltimore, Md). I had a question regarding themost aortic morphogenesis happens up until around age 18, could
you enlighten me, as I thought doxycycline was associated with
staining of teeth, which might prevent it from being useful in a
human setting? A parent might not want to give their child
doxycycline within a trial if it resulted in permanent brown staining
of their teeth, versus a drug like a losartan.
Dr Baxter. I agree with you. And, I think there is a question
about what the role of this would be along with losartan. Use of an
antihypertensive medication in a patient with, for example,
Raynaud’s who does not have hypertension, is often associated
with symptoms related to hypertension. Beta blockers have been
used for years in Marfan patients. My experience is that young
patients using beta blockers have a lot of side effects such as
depression and weight gain.
You are right about the teeth staining. This is not a drug that
you would want to start a child on at an early age. But there is a
large experience with doxycycline in kids with acne. I think doxy-
cycline might be an adjunct to other medical therapies in Marfan
patients.
Dr H. Atta (Cairo, Egypt). How did you choose this dose of
doxycycline? Was it based on previous reports? And, why didn’t
you choose more than one regimen?
Dr Baxter.This sounds like a lot of doxycycline. And, we have
done extensive work with doxycycline in our model of aortic
aneurysms. It turns out that if you took doxycycline 200 mg/day
that your plasma levels would be the same as the plasma levels in
these mice. And so, we chose this dose because it really is an
equivalent dose to 200 mg/day which is a normal dose of doxycy-
cline.
